Literature DB >> 7833058

Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma.

D R Fitzpatrick1, H Bielefeldt-Ohmann, R P Himbeck, A G Jarnicki, A L Marzo, B W Robinson.   

Abstract

Transforming growth factor-beta (TGF-beta) is produced by a number of tumor cell types including human malignant mesothelioma (MM), but its role as a direct or indirect factor in tumorigenesis is incompletely understood. We have investigated the expression of TGF-beta isoforms by human and murine MM cells and have analysed the effects of inducible antisense RNA-mediated inhibition of TGF-beta expression on murine MM in vitro and in vivo. The results showed that (a) TGF-beta 1 and -beta 2 were produced by both human and mouse MM cells, (b) antisense RNA against either TGF-beta 1 or -beta 2 cross-inhibited both TGF-beta 1 and -beta 2 expression, (c) inhibition of TGF-beta expression reduced the anchorage-independent growth of MM cells in vitro and the tumorigenicity of MM cells in vivo, and (d) inhibition of TGF-beta expression led to increased T lymphocyte infiltration into tumors. The data suggest that TGF-beta has multiple tumor-enhancing effects in MM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7833058     DOI: 10.3109/08977199409015049

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  15 in total

1.  Immunological alterations found in mesothelioma patients and supporting experimental evidence.

Authors:  Yoshie Miura; Yasumitsu Nishimura; Megumi Maeda; Shuko Murakami; Hiroaki Hayashi; Kazuya Fukuoka; Takumi Kishimoto; Takashi Nakano; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

2.  A novel transforming growth factor beta2 antisense transcript in mammalian lung.

Authors:  R K Coker; G J Laurent; K Dabbagh; J Dawson; R J McAnulty
Journal:  Biochem J       Date:  1998-06-01       Impact factor: 3.857

3.  Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma.

Authors:  Aki Murakami; Chiharu Tabata; Rie Tabata; Hisaya Okuwa; Takashi Nakano
Journal:  Oncol Lett       Date:  2011-12-23       Impact factor: 2.967

4.  Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.

Authors:  Zvi G Fridlender; Jing Sun; Sunil Singhal; Veena Kapoor; Guanjun Cheng; Eiji Suzuki; Steven M Albelda
Journal:  Mol Ther       Date:  2010-08-03       Impact factor: 11.454

5.  Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.

Authors:  Zvi G Fridlender; Veena Kapoor; George Buchlis; Guanjun Cheng; Jing Sun; Liang-Chuan S Wang; Sunil Singhal; Linda A Snyder; Steven M Albelda
Journal:  Am J Respir Cell Mol Biol       Date:  2010-04-15       Impact factor: 6.914

6.  TGF beta-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein.

Authors:  R E Herrera; T P Mäkelä; R A Weinberg
Journal:  Mol Biol Cell       Date:  1996-09       Impact factor: 4.138

Review 7.  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Authors:  J W Upham; M J Garlepp; A W Musk; B W Robinson
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

8.  Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.

Authors:  H Bielefeldt-Ohmann; A L Marzo; R P Himbeck; A G Jarnicki; B W Robinson; D R Fitzpatrick
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

9.  Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model.

Authors:  H Bielefeldt-Ohmann; D R Fitzpatrick; A L Marzo; A G Jarnicki; R P Himbeck; M R Davis; L S Manning; B W Robinson
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

10.  The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells.

Authors:  Jon G Quatromoni; Eiji Suzuki; Olugbenga Okusanya; Brendan F Judy; Pratik Bhojnagarwala; Ollin Venegas; Evgeniy Eruslanov; Jarrod D Predina; Steven M Albelda; Sunil Singhal
Journal:  BMC Immunol       Date:  2013-07-17       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.